Antibody-coated magnetic beads were crucial in the manufacturing process to achieve one-step cell isolation and activation, and enabled clinical-scale dose production within 2 to 3 weeks. Since then, the technology has become well established in the industry and has been used in over 200 clinical trials to provide critically needed treatment for patients. Despite these successes, challenges remain to further improve the reliability, consistency, and longevity of treatment outcomes. As well, there is still a need to accelerate and expand treatment delivery to patients. Download this application note to learn more how cell therapy system (CTS) Detachable Dynabeads CD3/CD28 were used to achieve one-step isolation and activation with flexible active release to optimize T cell phenotype.
You may also be interested in:
A streamlined manufacturing process is required in order to achieve high quality products in CAR-T therapy. The Thermo Fisher Scientific GibcoTM CTSTM DynaCellectTM Magnetic Separation System and fit-for-purpose consumables have been developed for automation of T cell isolation and activation using magnetic beads. The automated instrument performs cell separation and bead removal in a closed system by utilizing an integrated magnet-rocker and fluidic paths. Download this application note to learn more about the CTSTM DynaCellectTM Magnetic Separation System and its use in cell therapy manufacturing.
The GibcoTM CTSTM DynaCellectTM Magnetic Separation System will streamline your cell therapy development. The automated, closed system enables rapid isolation and bead removal for cell therapy manufacturing.
Download this brochure to learn more about the CTSTM DynaCellectTM Magnetic Separation System, that will enable you to scale your process from research to clinical manufacturing without sacrificing cell viability.